GSK-LSD1

• UNSPSC Description:

  GSK-LSD1 is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis[1][2][3].

• Target Antigen:

  Histone Demethylase

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Cancer; Infection; Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/gsk-lsd1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C1(N[C@H]2[C@H](C3=CC=CC=C3)C2)CCNCC1

• Molecular Weight:

  216.32

• References & Citations:

  [1]Ramms B, et al. Systemic LSD1 Inhibition Prevents Aberrant Remodeling of Metabolism in Obesity. Diabetes. 2022 Dec 1;71(12):2513-2529.|[2]Alsaqer SF, et al. Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis. Oncotarget. 2017 Jul 27;8(43):73372-73386.|[3]Hong KS, et al. GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro. Signal Transduct Target Ther. 2020 Nov 17;5(1):267.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1431368-48-7